Abstract 348P
Background
Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care for patients with NSCLC on the nutritional status, quality of life (QoL), psychological state and cancer pain.
Methods
In this randomised controlled trial, 120 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary outcome was the change in the quality of life, psychological state and nutritional status at 24 weeks. Analysis was by intention to treat.
Results
120 patients were enrolled: 60 in CEPC group (38 completed) and 60 in the SC group(32 completed). Patients in CEPC group had a better nutritional status [severe malnutrition: 11.67% (7/60); mild or moderate malnutrition: 61.67% (37/60); no malnutrition: 26.67% (16/60)] than SC group[severe malnutrition: 36.67% (22/60); mild or moderate malnutrition: 55.0% (33/60); no malnutrition: 8.3% (5/60)] (P=0.001). Furthermore, CEPC group had a better QoL than SC group (P<0.05). In addition, fewer patients in the CEPC group than in the SC group had depressive (P=0.005) symptoms. There was no significant difference in NRS score between CEPC group and SC group.
Conclusions
Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in nutritional status, quality of life and psychological state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
385P - Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
Presenter: Si-Yang Liu
Session: Poster viewing 05.
386P - Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
Presenter: Xin Li
Session: Poster viewing 05.
387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Presenter: Hidehito Horinouchi
Session: Poster viewing 05.
388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
Presenter: Yi-Long Wu
Session: Poster viewing 05.
389P - Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer
Presenter: Zhou Qing
Session: Poster viewing 05.
390P - Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Presenter: Haruyasu Murakami
Session: Poster viewing 05.
391P - Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Presenter: Goutam Panda
Session: Poster viewing 05.
392P - A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
Presenter: Jinji Yang
Session: Poster viewing 05.
394P - Research of the algorithm for rare driver genes in non-small cell lung cancer using pathological images and artificial intelligence
Presenter: Kiyotaka Yoh
Session: Poster viewing 05.
395P - Molecular landscape of Indian NSCLC: Is NGS the answer?
Presenter: Ullas Batra
Session: Poster viewing 05.